Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €51.95 EUR
Change Today +0.50 / 0.97%
Volume 235.0
As of 1:36 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by MERCK & CO. INC. (6MK) in the last 6 months

Announced 04/7/15
Arvinas, Inc.
Private Placement

Arvinas, Inc. announced that it will receive funding from new investor Merck & Co., Inc. on April 7, 2015. The terms of the transaction were not disclosed.


6MK's price was unchanged after the transaction was announced on 04/7/15.
Investor / Buyer
Merck & Co. Inc.
 
Announced 03/24/15
10.00B for Merck & Co. Inc.
Buyback

Merck & Co. Inc. (NYSE:MRK) announces a share repurchase program. Under the program, the company will repurchase up to $10,000 million worth of common stock. The repurchases will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. The shares will be repurchased for its treasury. The program reinforces company's commitment to deliver increased value to the shareholders and the Board's confidence ...
Read More


6MK's price was unchanged after the transaction was announced on 03/24/15.
 
Announced 02/23/15
106.00M for NGM Biopharmaceuticals, Inc.
Private Placement

NGM Biopharmaceuticals, Inc. announced that it will receive $106 million from new investor Merck & Co. Inc. on February 23, 2015. The investor will acquire 15% stake in the company. The round will be raised at a post-money valuation of $706 million. The funding raised will represent 20% premium to NGM’s most recent financing. The company has issued convertible series E preferred stock Pursuant to Regulation D.


6MK's price was unchanged after the transaction was announced on 02/23/15.
Investor / Buyer
Merck & Co. Inc.
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
6MK:GR €51.95 EUR +0.50

6MK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $151.11 USD +2.40
Amgen Inc $172.74 USD +7.20
Bayer AG €131.00 EUR +3.66
Gilead Sciences Inc $113.07 USD +2.53
GlaxoSmithKline PLC 1,329 GBp -4.50
View Industry Companies
 

Industry Analysis

6MK

Industry Average

Valuation 6MK Industry Range
Price/Earnings 14.8x
Price/Sales 3.9x
Price/Book 3.4x
Price/Cash Flow 14.4x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.